Premium
Immunotherapy of a mouse mammary carcinoma by sustained peritumor release of IL‐2
Author(s) -
Vaage Jan,
Mayhew Eric
Publication year - 1991
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910470417
Subject(s) - agar , liposome , phosphatidylcholine , phosphatidylglycerol , in vitro , carcinoma , chemistry , medicine , biology , pharmacology , pathology , biochemistry , phospholipid , bacteria , genetics , membrane
Abstract The purpose of this study was to compare the local and systemic therapeutic effects of lnterleukin‐2 (IL‐2) used in 3 different preparations: suspended in PBS, suspended in 2% agar, and entrapped in multi‐lamellar liposomes suspended in 2% agar. The liposomes were composed of phosphatidylglycerol and phosphatidylcholine in a 1:4 molar ratio. The net release of IL‐2 in vitro (by ELISA assay) at 37°C, measured at 4 hr, 2 days, and 10 days, was 50%, 75%, and 100% from agar, and 8%, 22%, and 33% from liposomes in agar. In the therapeutic tests, the IL‐2 preparations were injected close to s. c. implants of the MC2 mouse mammary carcinoma. Four injections at weekly intervals of IL‐2 in agar had as much local and systemic (against uninjected contralateral tumor implants in treated mice) therapeutic effect as the same total amount of IL‐2 in PBS given in 20 daily injections over 4 weeks. The IL‐2 liposome‐gel preparation was most effective (p < 0.05), probably due to the more sustained release of IL‐2. Three injections of this preparation gave a fixed and sustained peritumor release of IL‐2 which, at sub‐toxic levels, resulted in both local and systemic therapeutic effects.